The effect of a beta-3 adrenergic receptor agonist on metabolic disease in humans.

Not Applicable

• Conditions: Hepatic steatosis; Metabolic and Endocrine - Diabetes; Metabolic and Endocrine - Other endocrine disorders

• Registration Number: ACTRN12618001449224
• Lead Sponsor: Baker Heart and Diabetes Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-28
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age 20-50 years
BMI: 30-40 kg/m2
HOMA-IR: greater than or equal to 2.0

Exclusion Criteria

Alcohol consumption >3 (male) or >2 (female) standard drinks per day
Blood ALT concentration >3 times upper limit of normal (ULN) (ULN: female <20 IU/l, male <30 IU/l)
Hepatitis or autoimmune liver disease
History of type 1 or 2 diabetes
History of obstructive urinary symptoms
History of established cardiovascular disease (prior hospitalisation or medication for any cardiovascular disease or risk factor)
Currently taking any prescription medications that alter cardiometabolic parameters, prior use of anti-hypertensive medications and medications primarily acting via ß-ARs. Oral contraceptives are acceptable if treatment has been established for greater than 6 months.
Smoking
Established renal disease or eGFR <60 ml/min/1.73m2
Pregnant or breastfeeding women
History of cancer other than non-melanoma skin cancer
History of major psychiatric illness, psychosis or major depressive disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified